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Aim: To evaluate the utility of immunohistochemical staining of cytokeratin 19 (CK19), HBME-1, and galectin-3 in cell block
preparations of fine-needle aspiration cytology specimens as ancillary techniques for the differential diagnosis of papillary thyroid
carcinoma.
Materials and methods: Immunohistochemical detection of CK19, HBME-1, and galectin-3 was completed in 45 thyroid aspiration
cytology specimens fixed in paraffin-embedded blocks consisting of the following cytologic diagnoses: 1) 16 cases of papillary carcinoma,
2) 16 cases suspicious for papillary carcinoma, and 3) 13 cases involving nonneoplastic lesions.
Results: The follicular cells in the cytologically unequivocal papillary carcinoma diagnosis group expressed diffusely positive (+++)
CK19, HBME-1, and galectin-3 in 12/16, 12/16, and 14/16 cases, respectively. Diagnosis of papillary carcinoma was confirmed during
follow-up in all 16 cases. Positive staining for CK19 or galectin-3 was not detected among the 13 cases of cytologic and histopathologic
diagnosis of nonneoplastic lesions. CK19 (9/12) and galectin-3 (9/12) were diffusely positive (+++) in the majority of papillary carcinoma
samples with initial cytologic diagnostics indicating suspicion of papillary carcinoma.
Conclusion: The CK19, HBME-1, and galectin-3 immunostaining panel is a novel and informative adjunct for the diagnosis of papillary
thyroid carcinoma from cell block material. Diffuse immunostaining for CK19 and galectin-3 contributes to improvements in accurate
diagnosis of malignancy in cases of suspected papillary carcinoma.
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1. Introduction
Thyroid nodules occur commonly among the adult
population. Fine-needle aspiration (FNA) is a standard
procedure in determining a treatment course for thyroid
nodules. Thyroid FNA is used to triage patients for surgery,
or for conservative management of nodules. Patients with
FNA diagnoses that suggest malignancy and/or neoplasia
are typically managed surgically, while patients with
FNA results that indicate a benign lesion may be treated
clinically. Papillary thyroid carcinoma (PTC) is the most
common form of thyroid cancer. The cytologic criteria
necessary for definitive diagnosis of papillary carcinoma
from an FNA specimen include large monolayer sheets of
follicular epithelial cells with enlarged nuclei containing
fine and powdery chromatin, intranuclear cytoplasmic
inclusions with nuclear grooves, and papillary structures
(1). However, in a subset of cases that lack one or more
of these defining features, accurate diagnosis of papillary
carcinoma is challenging.
* Correspondence: hhaltas@hotmail.com

A number of immunocytochemical markers are
available that may distinguish nonneoplastic lesions of the
thyroid from papillary carcinoma and its variants (2–9).
The type I intermediate filament protein cytokeratin
polypeptide 19 (CK19) is the smallest known keratin and
is unique in that, contrary to all other known keratins,
it does not have a conjugate partner for the formation
of filaments. This distinct feature of CK19 implies that
regulation of CK19 expression differs from that of other
keratin-encoding genes (10). CK19 is a sensitive marker
for papillary carcinomas, usually apparent as diffuse
cytoplasmic positive staining in these tissues (2,4,11,12).
HBME-1 was originally described as a specific marker of
mesothelial cells. In the literature, a number of studies
have demonstrated the utility of HBME-1 membranous
and cytoplasmic immunostaining in the identification of
malignant follicular epithelial lesions of the thyroid (13–
16). Galectin-3 is a member of a family of b-galactoside
binding animal lectins. Galectin-3 is expressed by many
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tissues and cell types in both the nucleus and in the
cytoplasm and has multiple functions including cell–cell
and cell–matrix adhesion, cell growth, cell cycle regulation
and apoptosis, neoplastic transformation and spread, and
cell repair processes. Galectin-3 is highly up-regulated in
thyroid carcinoma of follicular cell origin (17).
The objective of the current study was to examine the
utility of galectin-3, HBME-1, and CK19 immunostaining
in FNA-derived cell block material for the diagnosis of
papillary carcinoma of the thyroid.
2. Materials and methods
FNA cytology and cell blocks were obtained from the
archives of the Department of Pathology, Fatih University
Faculty of Medicine, from January 2009 to July 2012.
Only cases with an adequate number of cell blocks and
available histologic follow-up were included in this study.
The cytologic diagnoses issued for the cell blocks from
Papanicolaou- and May-Grünwald Giemsa (MGG)stained cytology smears included: 1) papillary carcinoma
(16 cases), 2) suspected papillary carcinoma (16 cases),
and 3) nonneoplastic lesions (13 cases).
2.1. Cell block preparation
Following smear preparations, the needles and syringes
used to obtain fine-needle aspirates were rinsed in 10 mL
of an alcohol–formalin mixture (a final concentration
of 90% ethanol and 10% formaldehyde was used) in a
specimen container. After 30 min, any residual clot or
tissue in the hub of needles was carefully removed in the
laboratory with the aid of another needle. The entire tissue
was processed in a fashion similar to a small biopsy, with
the tissue impregnated and embedded in paraffin. In each
case, hematoxylin and eosin staining was performed on
4-µm-thick sections of the cell block.
2.2. Immunohistochemical analysis
The 4-µm-thick sections were cut from blocks of
paraffin-embedded tissue, deparaffinized, and rehydrated
according to standard methods. Slides were incubated in
hydrogen peroxide block for 15 min to reduce nonspecific
background staining due to endogenous peroxidase.
Antigen retrieval was performed by incubating the slides
for 15 min with pepsin (LabVision; catalog no. AP-9007),
at a concentration of 1 mg/mL, prior to immunostaining
for CK19. Prior to HBME-1 and galectin-3 staining,
slides were microwaved in 10 mM citric acid at pH
6.0 for 20 min. The slides were incubated for 60 min in
primary antibody solution against CK19 (clone RCK108,
LabVision/NeoMarkers; 1:100), HBME-1 (clone HBME-1,
LabVision/NeoMarkers; 1:25), and Galectin-3 (clone 9C4,
NovoCastra; 1:100) at room temperature (20–24 °C). The
standard avidin–biotin–peroxidase complex technique
was performed using the LabVision Secondary Detection
Kit (UltraVision Detection System Anti-polyvalent, HRP),
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with appropriate positive and negative controls. The
chromogen used was AEC. All slides were counterstained
using Mayer’s hematoxylin.
2.3. Microscopic evaluation
Immunoreactivity was designated as negative, focally
positive (+: less than 25% of cells reactive), positive (++:
25–50%), or diffusely positive (+++: more than 75%),
according to the extent of the reaction. Reactivity in more
than 25% of cells at an intensity of at least ++ was defined
as positive (5,18).
Sensitivity, specificity, positive predictive value (PPV),
negative predictive value (NPV), and diagnostic accuracy
were calculated for each antibody, using histologic
diagnosis as the standard of comparison for each of the 3
specific immunostains.
3. Results
Clinical and immunohistochemical data relating to each
case are summarized in Table 1. Figures 1A–1F illustrate the
cytologic morphology of various thyroid nodules from cell
blocks and FNA biopsies. Benign and malignant follicular
cells were observed in both cell block preparations and
FNA biopsies. However, thyroid tissue fragments were
observed only in the cell block sections (Figures 1D–1F).
Similar to the corresponding tissue sections (Figures 1G–
1I), tissue architecture was apparent in the fragmented
tissue section (Figures 1D–1F).
In the 16 cases with an unequivocal papillary carcinoma
cytologic diagnosis, 12 (75%) cases demonstrated intense
and diffuse (+++) cytoplasmic staining for CK19, 3 (19%)
cases demonstrated moderate (++) staining, and 1 (6%)
case was weakly positive for CK19. The incidence of diffuse
(+++) cytoplasmic and membranous staining for HBME-1
and galectin-3 among these 16 cases was 75% and 86%,
respectively.
Among the 12 cases with an initial cytologic diagnosis
of suspicion of papillary carcinoma and a final diagnosis
confirming papillary carcinoma, the detection rates of
diffuse CK19, HBME-1, and galectin-3 positivity were
75%, 25%, and 75%, respectively.
In 4 cases with an initial cytologic diagnosis of suspicion
of papillary carcinoma and a final diagnosis confirming
papillary carcinoma, staining of CK19, HBME-1, and
galectin-3 was not detected.
Among the 13 cases (100%) with cytologic and
histologic diagnosis of nonneoplastic lesions, neither
CK19 nor Galectin-3 staining was observed. HBME-1
staining was detected (+++) in only one case of cellular
microfollicular configuration.
Clearly, the intensity of galectin-3, HBME-1, and
CK19 staining, as well as the number of positive cells, was
enhanced in malignancy (Figures 1J–1R). The specificity,
sensitivity, and PPV of HBME-1, CK19, and galectin-3 in
distinguishing between PTC and nonneoplastic lesions
were calculated and are presented in Table 2.
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Figure. These photomicrographs provide a morphologic comparison of thyroid lesions on MGG-stained FNA cytology smears, cell
block preparations, and tissue sections with immunostaining of CK19, HBME-1, and galectin-3 on cell blocks. The FNA cytology
demonstrates benign, malign, and suspicious for papillary carcinoma follicular epithelial cells in (A) adenomatous nodule; (B) papillary
hyperplasia (suspicious for papillary carcinoma); and (C) a papillary group of cancer cells, PTC. (D–F) Fragments of thyroid tissue
are observed in these cell block sections. Thyroidectomy specimens revealed that the lesions were distributed. (G) An example of
adenomatous nodule, (H) papillary hyperplastic lesions, and (I) classic variant papillary carcinoma. Immunodetection demonstrated
weak staining for (J) CK19, (M) HBME-1, and (P) galectin-3 in adenomatous nodules. The atypical follicular epithelial cells were
diffusely immunostained for CK19, HBME-1, and galectin-3 in (L, O, R) papillary carcinoma.
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Table 1. Clinicopathological and immunohistochemical features of thyroid nodules diagnosed by means of FNA cytology.
No.

Total

Sex/Age

Cytologic diagnosis

Final diagnosis

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

F/53
F/30
F/61
F/45
F/43
F/55
F/48
F/19
F/46
F/44
F/31
F/32
F/43
F/33
M/53
F/32
F/47
M/57
F/34
F/65
N/43
M/18
F/38
F/72
F/17
F/29
F/33
F/58
F/41
F/52
F/36
F/31
F/29
F/40
F/82
F/52
F/47
F/29
F/67
F/41
F/42
F/56
F/56
M/63
F/62

PTC
susp PTC
susp PTC
susp PTC
susp PTC
susp PTC
susp PTC
NL
NL
NL
susp PTC
NL
NL
susp PTC
susp PTC
PTC
NL
PTC
susp PTC
susp PTC
NL
PTC
PTC
susp PTC
PTC
PTC
PTC
PTC
PTC
susp PTC
susp PTC
PTC
PTC
PTC
PTC
susp PTC
susp PTC
PTC
PTC
NL
NL
NL
NL
NL
NL

PTC
NL
PTC
PTC
PTC
PTC
PTC
NL
NL
NL
PTC
NL
NL
PTC
NL
PTC
NL
PTC
NL
PTC
NL
PTC
PTC
PTC
PTC
PTC
PTC
PTC
PTC
PTC
PTC
PTC
PTC
PTC
PTC
PTC
NL
PTC
PTC
NL
NL
NL
NL
NL
NL

N

45

45

45

Immunohistochemistry
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++
+++
+++
+++
+++
+
++
++
+++
+
+++
+
+++
+++
+
+++
+++
++
+++
++
+++
+++
+++
+++
+++
++
+++
+++
+++
+++

+
++
+++
+++
+++
+++
+
+
+
+
+
+++
+
+++
+
+++

+++
+
+
-

+
+
+
+
+
+
++
+
++
+++
+++
+
+++
+++
+++
+++
+++
+++
+
+++
++
+++
+++
+
+++
+++
+++
+++
++
+++
+
+
-

+++
+++
+++
++
+++
+++
+++
+++
+++
+++
+++
+++
+++
+++
+++
+++
++
+++
+
+
+
+
++
+

45

45

45

-

PTC, Papillary thyroid carcinoma; susp PTC, suspicious for papillary thyroid carcinoma; NL, nonneoplastic lesion.

628

-

HALTAŞ et al. / Turk J Med Sci
Table 2. Sensitivity, specificity, PPV, NPV, and diagnostic accuracy of immunohistochemical markers for papillary thyroid

carcinoma

HBME-1

CK19

Galectin-3

Sensitivity

64%

93%

92%

Specificity

88%

94%

82%

PPV

0.90

0.96

0.89

NPV

0.60

0.89

0.78

Diagnostic accuracy

73%

93%

84%

4. Discussion
The majority of PTCs are readily diagnosed using classic
cytologic criteria, allowing the pathologist to differentiate
benign lesions from papillary carcinomas with high
precision. However, in a minority of cases, the pathologist
is confronted with thyroid lesions in which the distinction
between papillary carcinomas and benign lesions may be
quite subtle. To aid in the diagnosis of papillary thyroid
carcinoma, a variety of immunohistochemical stains have
been evaluated in thyroid FNA cytology (2,6,8,18,19).
Unfortunately, the immunoexpression profile of papillary
carcinomas and benign lesions of the thyroid overlap
significantly, and, to the best of the present authors’
knowledge, no single marker or even panel is 100%
sensitive and 100% specific for differentiation of papillary
carcinoma and benign thyroid lesion.
In this study, we evaluated the ability of 3 markers
(HBME-1, CK19, and galectin-3) to differentiate papillary
carcinoma from benign lesions of the thyroid in FNA cell
blocks. The advantages of immunohistochemical staining
of paraffin blocks over direct tissue smears are the ability to
store paraffin blocks for long periods of time and, therefore,
the number of samples that can be acquired for study. The
disadvantages of direct immunostaining of tissue smears
include artificially high and nonspecific staining resulting
from disrupted cells and membrane fragments sticking to
the slides, the lack of parallel samples of comparable cells for
control or replicate testing, and increased cost due to the use
of a considerable volume of antibodies to cover large areas
of diffuse tissue smears. In contrast, cell blocks are found
to be highly suitable for immunohistochemistry due to ease
of morphological interpretation, standardized comparison
with surgical pathology material, minimal background
staining, and anticipated immunostaining patterns (20).
CK19 is a low-molecular-weight keratin widely
expressed in epithelial cells. CK19 is a minor component of
stratified epithelium, such as basal cell layers (21). The use
of CK19 immunostaining has been reported in cytology
smears of thyroid nodules. CK19 is a sensitive marker
for papillary carcinomas, with positive immunostaining
indicated by diffuse cytoplasmic reactivity (2,6). Several

studies have reported that CK19 is expressed focally in
normal thyroid epithelium, Hashimoto’s thyroiditis, and
in some benign tumors. Diffuse CK19 positive staining
may have diagnostic value in PTC (2,4,6,11,12,22). In
the present study, 75% of papillary carcinoma cases were
strongly positive for CK19, and 3.57% of cases were
negative or expressed CK19 weakly. In addition, focal
staining was present in 5 (29.41%) of 17 benign lesions.
Diffuse, strong immunostaining with CK19 was not
observed in nonneoplastic lesions.
The monoclonal antibody HBME-1 binds to an
unknown microvillus surface antigen that is present in
normal or neoplastic mesothelial cells, as well as in other
epithelial cells. Previous studies have reported that HBME1 is a sensitive marker for PTCs with a staining pattern that
is predominantly membranous with variable cytoplasmic
positivity (18,22). In the present study we observed
HBME-1 positivity in 64.28% of papillary carcinoma
cases. There was no diffuse staining with HBME-1 in
58.82% of the nonneoplastic lesions. Only a single case
of microfollicular hyperplasia in a nonneoplastic lesion
showed diffuse positive staining with HBME-1.
Galectin-3 is a β-galactosyl-binding lectin protein
involved in a variety of biological functions, including
cell-cycle regulation, apoptosis, cell adhesion, and
tumor progression. The biological function of galectin-3
expression in transformed thyrocytes is not well
understood. In the published literature, many studies have
demonstrated that well-differentiated thyroid carcinomas
frequently express galectin-3, whereas healthy thyroid
tissue and the majority of benign thyroid proliferations
do not (3,8,23). These findings strongly support the use of
galectin-3 immunostaining in preoperative FNA cytology
as an adjunct marker for interpreting difficult pathologic
cases, especially in confirming suspected malignant
neoplasm (3,8,23,24). The sensitivity and specificity of
galectin-3 in thyroid carcinomas were 99% and 98%,
respectively, in a study by Bartolazzi et al. (3). In the present
study, the observed specificity of galectin-3 in thyroid
carcinomas was 82%. However, some researchers reported
conflicting results with the use of the galectin-3-expression
test in the diagnosis of follicular thyroid proliferations
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(25,26). According to Bartolazzi et al., the controversy
may result from methodological issues. According to
these researchers, optimum galectin-3-expression analysis
requires formalin-fixed and paraffin-embedded cytological
preparations and a biotin-free immunohistocytochemical
detection method. It is almost impossible to correctly
perform galectin-3 immunostaining using conventional
cytological smears (3).

HBME-1, CK19, and galectin-3 are functional markers
for diagnosing PTC using paraffin cell block material.
Diffuse CK19 and/or galectin-3 immunopositivity
confirms papillary cell differentiation. The sensitivity
of HBME-1 is lower than that of CK19 and galectin-3
in diagnosis of PTC. We recommend the use of this
immunostaining panel in cases with features prompting
suspicion of PTC.
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